3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $9M | -$81M | 0.0% | -1031.5% | -$82M | $3M | $189M |
| 2024 | $0 | -$71M | — | — | -$52M | $9M | $354M |
| 2023 | — | -$64M | — | — | -$38M | $14M | $22M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $3M | -$22M | 0.0% | -915.4% | -$24M | — | $242M |
| Dec '25 | $3M | -$26M | 0.0% | -923.4% | -$28M | $3M | $189M |
| Sep '25 | $2M | -$20M | 0.0% | -1126.6% | -$16M | $4M | $216M |
| Jun '25 | $2M | -$22M | 0.0% | -1027.0% | -$20M | $6M | $220M |
| Mar '25 | $1M | -$13M | 0.0% | -1133.4% | -$18M | $7M | $257M |
| Dec '24 | $0 | -$21M | — | — | -$5M | $9M | $354M |
| Sep '24 | $0 | -$23M | — | — | -$15M | $10M | $334M |
| Jun '24 | $0 | -$14M | — | — | -$16M | — | — |
| Mar '24 | — | -$13M | — | — | -$16M | — | $174M |
| Dec '23 | — | -$21M | — | — | -$9M | $14M | $22M |
| Sep '23 | — | -$15M | — | — | — | — | — |
| Jun '23 | — | -$17M | — | — | — | — | — |
| Mar '23 | — | -$11M | — | — | — | — | — |
How the market has priced BIOA against its own fundamentals since 2024-09 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
See the revenue and net-income charts above for Bioage Labs, Inc.'s multi-year trend.
As of FY2025, Bioage Labs, Inc. reported $3M of total debt against $189M of cash; operating income covered interest expense -133.1×.
In FY2025, gross margin was —, operating margin -1031.5%, and net margin -896.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.